ClinicalTrials.gg
Active, not recruitingNCT02086890Updated Feb 27, 2026

Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

An interventional study of Electro-acupuncture and Laser Acupuncture in Retinitis Pigmentosa, sponsored by Nova Southeastern University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Nova Southeastern University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Planned enrollment
39th of 78
21 · median 21
Started
2014
with 4 others
No phase
19 of 119
1 open now
Primary completion
2026-12
later than 11 of 41 live
Registered
40th of 119
by date

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 39th largest by planned enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2014, is one of 19 with no phase, reaches primary completion later than 11 of the 41 other live ones, and was the 40th registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

Measures of vision in RP patients receiving promising therapy using transcorneal electrical stimulation.

Read the detailed description

Retinitis pigmentosa (RP) is a slowly progressive retinal degeneration for which there is no proven treatment. Patients are interested in trying alternative therapies to try to reduce their vision loss, but only limited research evidence exists to support their use and potential benefit. The goal of this research project is to gain a better understanding of possible changes in ocular and retinal blood flow and measures of vision in RP patients receiving two promising therapies, electroacupuncture and transcorneal electrical stimulation. We are currently only doing transcorneal electrical stimulation.

03

Conditions studied

  • Retinitis Pigmentosa

Browse trials for

Keywords

  • retinitis pigmentosa
  • acupuncture
  • electroacupuncture
  • transcorneal electrical stimulation
  • microcurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18+
  • Diagnosis of retinitis pigmentosa (RP)
  • Best-corrected visual acuity better than 20/400 in at least one eye
  • More than 20% loss of Goldmann Visual Field area (III4e test target) in at least one eye
  • Able and willing to participate in all study visits for a \~4-6 month period
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Very severe vision losses in both eyes (e.g., hand motions or light perception only) with difficulty performing the proposed vision tests
  • Vision loss due to ocular diseases other than RP, cystoid macular edema, or cataracts
  • Schedules do not permit participation in all study visits
  • Previous acupuncture or TES treatment for RP
  • Inability to understand study procedures or communicate responses to visual stimuli in a consistent manner (cognitive impairment)
  • Dementia; Long or short-term memory loss
  • Unable to read or speak English
  • Smoking, excessive alcohol, or illegal drug use
  • Receiving current psychiatric care (i.e. unstable emotional and mental health status)
  • History of excessive bleeding
  • Reduced general health and/or systemic medications that may diminish the potential response to the electroacupuncture treatments
  • Implanted cardiac pacemaker
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Electro-acupuncture

    Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks

    Device: Electro-acupuncture

  • Sham comparator
    Sham Electro-acupuncture

    No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks

    Device: Sham Electro-acupuncture

  • Experimental
    Laser acupuncture

    Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period

    Device: Laser Acupuncture

  • Sham comparator
    Sham Laser acupuncture

    An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period

    Device: Sham laser acupuncture

  • Experimental
    Transcorneal Electrical Stimulation

    Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions

    Device: Transcorneal Electrical Stimulation

  • Sham comparator
    Sham Transcorneal Electrical Stimulation

    Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions

    Device: Sham transcorneal electrical stimulation

Interventions

  • DeviceElectro-acupuncture
  • DeviceLaser Acupuncture
  • DeviceTranscorneal Electrical Stimulation
  • DeviceSham Electro-acupuncture
  • DeviceSham laser acupuncture
  • DeviceSham transcorneal electrical stimulation
06

What researchers measure

Primary outcomes

  1. Significant changes from baseline in Goldmann visual field area in both eyes

    Using Haig-Streit Octopus perimeter

    Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation

Secondary outcomes

  1. Significant changes from baseline in best-corrected ETDRS visual acuity at both 2 weeks and 6 weeks post-intervention initiation

    Using Pelli-Robson visual acuity charts

    Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation

  2. Changes in Macular edema Optical Coherence Tomography (OCT)

    Using Optical Coherence Tomography

    Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation

  3. Significant changes from baseline in contrast sensitivity at both 2 weeks and 6 weeks post-intervention initiation

    Using Adaptive Sensory Technology Quick CSF

    Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation

  4. Significant changes from baseline in Dark adaptation function at both 2 weeks and 6 weeks post-intervention initiation

    Using the AdaptDx by Maculogix

    Time frame: twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation

07

Study locations

1 site
08

References and documents

Publications

  • Bittner AK, Gould JM, Rosenfarb A, Rozanski C, Dagnelie G. A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients. Clin Exp Optom. 2014 May;97(3):240-7. doi: 10.1111/cxo.12117. Epub 2013 Oct 29. PubMed 24773463 ↗
  • Bittner AK, Seger K. Longevity of visual improvements following transcorneal electrical stimulation and efficacy of retreatment in three individuals with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):299-306. doi: 10.1007/s00417-017-3858-8. Epub 2017 Dec 8. PubMed 29222719 ↗
  • Bittner AK, Seger K, Salveson R, Kayser S, Morrison N, Vargas P, Mendelsohn D, Han J, Bi H, Dagnelie G, Benavente A, Ramella-Roman J. Randomized controlled trial of electro-stimulation therapies to modulate retinal blood flow and visual function in retinitis pigmentosa. Acta Ophthalmol. 2018 May;96(3):e366-e376. doi: 10.1111/aos.13581. Epub 2017 Nov 11. PubMed 29130647 ↗
  • Kayser S, Vargas P, Mendelsohn D, Han J, Bi H, Benavente A, Bittner AK. Reduced Central Retinal Artery Blood Flow Is Related to Impaired Central Visual Function in Retinitis Pigmentosa Patients. Curr Eye Res. 2017 Nov;42(11):1503-1510. doi: 10.1080/02713683.2017.1338350. Epub 2017 Sep 14. PubMed 28910168 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2014 (actual). Primary completion is estimated for Dec 2026, 148 months after the start.

Of 30 interventional studies with no phase under Retinitis Pigmentosa, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 154. This study's planned 148 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2014
First posted
Mar 13, 2014
StartActual
Aug 13, 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02086890
Lead sponsor
Nova Southeastern University
Responsible party
Kenneth Seger (Associate Professor, HPD-College of Optometry, Nova Southeastern University) — Principal investigator
First posted
Mar 13, 2014
Start date
Aug 13, 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Kenneth R Seger, OD, MSc
principal investigator · Faculty

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion